Trial Profile

LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darapladib (Primary)
Indications Cardiovascular disorders; Coronary disorders; Myocardial infarction; Stroke
Focus Registrational; Therapeutic Use
Acronyms STABILITY
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

25 Sep 2021 Results of a retrospective cohort study assessing interaction between diabetes status and Lp-PLA2 activity with risk of MCE ; using data from two clinical studies: GoDARTS and STABILITY published in the Diabetologia
02 Jan 2021 Results (n=13153) of a substudy published in the American Heart Journal
18 Apr 2020 Results (n=13,623 ) published in the American Heart Journal

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com